期刊
CLINICAL OPHTHALMOLOGY
卷 15, 期 -, 页码 3747-3755出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OPTH.S231801
关键词
Ang/Tie; faricimab; YOSEMITE; RHINE; TENAYA; LUCERNE
The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab, a bispecific antibody targeting VEGF and Ang2, has shown positive results in patients with DME and AMD, potentially changing the treatment landscape.
The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据